A5046416857- HIV Research and Treatment
- Hepatitis B Virus Studies
- Viral Infections and Outbreaks Research
- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- CRISPR and Genetic Engineering
University of Nebraska Medical Center
2022-2023
Treatment of HIV-1 ADA -infected CD34+ NSG-humanized mice with long-acting ester prodrugs cabotegravir, lamivudine, and abacavir in combination native rilpivirine was followed by dual CRISPR-Cas9 C-C chemokine receptor type five (CCR5) proviral DNA gene editing. This led to sequential viral suppression, restoration absolute human CD4 + T cell numbers, then elimination replication-competent virus 58% infected mice. Dual CRISPR therapies enabled the excision integrated cells contained within...
Treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy. However, suboptimal adherence to the existing therapy has led need for ultralong-acting antivirals. A lipophilic and hydrophobic ProTide was made by replacing alanyl isopropyl ester present in tenofovir alafenamide (TAF) with a docosyl phenyl ester, now referred as M1TFV. NM1TFV nanoformulated TAF (NTAF) nanocrystals were formulated high-pressure homogenization. single intramuscular injection NM1TFV, but not NTAF,...